The invention provides application of an antibiotic substitute
drug melatonin in preventing the infection of
meningitis escherichia coli pathogens on child patients.
Meningitis-type
escherichia coli is separated and identified from muscovy duck
cerebrospinal fluid, a
meningitis model of 3-week-old
ICR mice is constructed for the first time by utilizing the strain, and the successful construction of the mouse
meningitis model is evaluated from the aspects of neurological symptom scoring, mortality difference statistics, the damage degree of a blood-brain barrier, expression of meningitis-related
inflammatory factors and the like respectively. With
antibiotics as references, the mice are treated with the
melatonin and the four
combined antibiotics respectively, one week later, the
disease onset conditions of the meningitis mice are detected, results show that through the
melatonin and the
combined use of the
antibiotics, the neurological symptoms of the meningitis mice can both be reduced, the
survival rate of the meningitis mice is increased, integrity keeping of the blood-brain barrier is promoted by the melatonin, the invasion of inflammatory cells into the central nervous systemis reduced, the
disease onset of the meningitis in the mice is prevented through the function of the brain-gut axis, and a new antibiotic substitute and
treatment strategy are provided for preventingneonatal meningitis diseases.